Healio’s latest tales in glaucoma embrace the de novo classification of an ocular strain adjusting pump and promising outcomes with timolol microdrops to decrease IOP.
Take a look at these glaucoma articles and extra beneath.
Healio’s latest tales in glaucoma embrace the de novo classification of an ocular strain adjusting pump and promising outcomes with timolol microdrops to decrease IOP.
Picture: Adobe Inventory
FDA grants de novo classification to Fysx ocular strain adjusting pump
The FDA granted de novo classification to the Fysx ocular strain adjusting pump for sufferers with normal-tension glaucoma or open-angle glaucoma with IOP of 21 mm Hg or much less, in line with a press launch from Steadiness Ophthalmics. Learn extra.
Timolol microdrops seem as efficient as typical drops in decreasing IOP
Timolol maleate 0.5% microdrops delivered with the Nanodropper Adaptor met three noninferiority endpoints in decreasing IOP in contrast with typical timolol drops. Learn extra.
‘Take a look at entire image’ to detect glaucoma development
To detect glaucoma development, physicians want to take a look at all out there knowledge and imaging, in line with a presentation at Actual World Ophthalmology. Learn extra.
Sustained-release bimatoprost implant reveals security, efficacy in early examine
A sustained-release bimatoprost drug supply platform reveals promise within the remedy of ocular hypertension and open-angle glaucoma, in line with a poster on the American Society of Cataract and Refractive Surgical procedure assembly. Learn extra.
Alcon acquires Belkin Imaginative and prescient, direct selective laser trabeculoplasty gadget
Alcon accomplished the acquisition of Belkin Imaginative and prescient, together with its direct selective laser trabeculoplasty expertise. Learn extra.
